SUPN SUPERNUS PHARMACEUTICALS, INC.
Research report · from SEC EDGAR · close 2026-07-10
$48.46 -0.6%
$2.81B mkt cap
executive summary
SUPERNUS PHARMACEUTICALS, INC. (SUPN) is a $2.81B company. Revenue is $719.0M (+8.6% y/y) at a -5% net margin. It is not yet profitable. Our health score is C (68/100). 1 red flag on file. Held by 1 tracked funds. It funds itself; low dilution risk.
Revenue (FY)
$719.0M
+8.6% y/y
⚠One-sided insider selling
7 insider sales and no open-market buys in the recent window.
who's buying
Insider buys / sells
0 / 7
Cash & ST investments
$184.9M
Operating cash flow
$47.3M
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-10 by stocktools.ai.